Armed with $270M in capital, Scorpion Therapeutics aims to broaden the reach of precision oncology

Founded in 2020, Scorpion is agnostic about the potential therapies and targets it will explore with what it describes as its drug-hunting engine. But the company is hoping to unveil its first drug candidate this year.